← Leaderboards
Losee Lucy Ling
Novobiotic Pharmaceuticals, Llc
$17,993,656
Attributed
$17,993,656
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.4M · FY2005–21$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$17,993,656 · 12
By mechanism
R44$14,374,514 · 4
R43$2,686,269 · 7
R01$932,873 · 1
Top collaborators
No co-investigators on record.
Most similar at Novobiotic Pharmaceuticals, Llc
Same institution · by research overlap
- Dallas Hughes$18,700,713
- Amy Lynn Spoering$8,494,670
Others in their field
Top investigators on “Antibiotics”
- Laurence H Baker · University Of Michigan At Ann Arbor$52,071,546
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,812,829
- Taha E Taha · Johns Hopkins University$37,363,329
- Urs Ochsner · Crestone, Inc.$36,950,837
- Deborah T Hung · Massachusetts General Hospital$36,871,538
- Ryan Cirz · Revagenix, Inc.$35,410,554
Research focus
AntibioticsPathogenAntimicrobialMicroorganismLeadIn VitroMulti-Drug ResistanceStructureToxic EffectPharmaceutical PreparationsMicrobialResistanceInfectionSourceTechnologyAcuteAnimal ModelBaseSoilProgramsEvaluationDrug DiscoveryGrowthBacteria
Grant awards (22)
Preclinical development of Novo29, a new antibiotic$977,463
R44 · FY2021 · AI · contact PI
Preclinical development of Novo29, a new antibiotic$987,424
R44 · FY2020 · AI · contact PI
Preclinical development of Novo29, a new antibiotic$999,992
R44 · FY2019 · AI · contact PI
Preclinical development of Novo29, a new antibiotic$231,409
R43 · FY2018 · AI · contact PI
Specific anti-TB compounds from uncultured bacteria$219,069
R43 · FY2015 · AI · contact PI
UV-Based Approach for Accessing New Antibiotics$299,973
R43 · FY2013 · AI · contact PI
Isolating novel fungi for antibiotic discovery$999,313
R44 · FY2012 · AI · contact PI
UV-Based Approach for Accessing New Antibiotics$299,973
R43 · FY2012 · AI · contact PI
Isolating novel fungi for antibiotic discovery$999,832
R44 · FY2011 · AI · contact PI
Isolating novel actinomycetes for antibiotic discovery$999,586
R44 · FY2011 · AI · contact PI
Isolating novel actinomycetes for antibiotic discovery$999,461
R44 · FY2010 · AI · contact PI
Isolating novel fungi for antibiotic discovery$999,356
R44 · FY2010 · AI · contact PI
Isolating novel actinomycetes for antibiotic discovery$999,308
R44 · FY2009 · AI · contact PI
Developing Novel Antibiotics Against Yersinia pestis$1,805,783
R44 · FY2008 · AI · contact PI
Isolating novel fungi for antibiotic discovery$299,258
R43 · FY2008 · AI · contact PI
Isolating novel actinomycetes for antibiotic discovery$299,000
R43 · FY2008 · AI · contact PI
Developing Novel Antibiotics Against Yersinia pestis$1,811,326
R44 · FY2007 · AI · contact PI
Developing Novel Antibiotics Against Yersinia pestis$1,795,670
R44 · FY2006 · AI · contact PI
Novel Approaches to Accessing Secondary Metabolites$499,789
R43 · FY2006 · AI · contact PI
Novel Antibiotics from Unculturable Actinomycetes$932,873
R01 · FY2005 · AI
Developing Novel Antibiotics Against Yersinia pestis$304,709
R43 · FY2005 · AI
Developing Novel Antibiotics Against Yersinia pestis$233,089
R43 · FY2004 · AI